New Content  edit
Get The App!

Loading the player...
HRQoL and Efficacy with Myelofibrosis Patients in the Phase III Persist-1 Trial of Pacritinib Vs BAT
Share URL
Embed Code
Share by Email
Send to social websites
Report this video as inappropriate You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email. Select your reason
Sexual Content Violent or Repulsive Content
Hateful or Abusive Content Harmful Dangerous Acts
Child Abuse Spam
At ASH 2015, Dr. Ruben Mesa from the Mayo Clinic in Phoenix discusses his poster titled "Relationship Between Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HRQoL) and Efficacy in Patients with Myelofibrosis in the Phase III Persist-1 Trial of Pacritinib Vs. Best Available Therapy (BAT)."